Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Abstract— The work is aimed at the synthesis and analysis from NS4A of hepatitis C virus (HCV) antigen peptide fragment that contains a conserved B-cell and T-helper epitopes. The 24-mer peptide VIVGRIILSGRPAVIPDREVLYRK-NH2, which contains the main immunogenic site 24–46 of HCV NS4A antigen (corresponding to the 1681–1703 amino acid residues of the HCV polypeptide), subtype 1b, has been prepared via solid-phase synthesis according to the Fmoc-protocol. Particles with diameters of 73 ± 10 nm (30%) and 236 ± 5 nm (70%) have been detected in the water solution of the highly purified peptide (0.5 mg/mL) by dynamic light scattering. The polydispersity index of 0.377 ± 0.012 implies the existence of heterogeneity because of the aggregation of the peptide molecules. The ζ-potential of the peptide aggregates has been determined as 7.0 ± 0.5 mV by means of electrophoretic light scattering. These data confirm the possibility for the development of a nanoscale liposome form of the peptide preparation. Immunoreactivity of the synthesized highly purified peptide has been studied with the use of blood sera of patients with chronic hepatitis C. Antipeptide immunoglobulins G have been detected in 41.7% of serum samples. Thus, this peptide has been shown to reproduce at least one B-epitope, to which antibodies are raised during natural HCV infection. The synthesized 24-mer peptide is a promising candidate for further research and for use as a potential immunogen for the design of a nanoscale therapeutic immunogenic liposomal peptide composition with synthetic lipids as an adjuvant.
Abstract— The work is aimed at the synthesis and analysis from NS4A of hepatitis C virus (HCV) antigen peptide fragment that contains a conserved B-cell and T-helper epitopes. The 24-mer peptide VIVGRIILSGRPAVIPDREVLYRK-NH2, which contains the main immunogenic site 24–46 of HCV NS4A antigen (corresponding to the 1681–1703 amino acid residues of the HCV polypeptide), subtype 1b, has been prepared via solid-phase synthesis according to the Fmoc-protocol. Particles with diameters of 73 ± 10 nm (30%) and 236 ± 5 nm (70%) have been detected in the water solution of the highly purified peptide (0.5 mg/mL) by dynamic light scattering. The polydispersity index of 0.377 ± 0.012 implies the existence of heterogeneity because of the aggregation of the peptide molecules. The ζ-potential of the peptide aggregates has been determined as 7.0 ± 0.5 mV by means of electrophoretic light scattering. These data confirm the possibility for the development of a nanoscale liposome form of the peptide preparation. Immunoreactivity of the synthesized highly purified peptide has been studied with the use of blood sera of patients with chronic hepatitis C. Antipeptide immunoglobulins G have been detected in 41.7% of serum samples. Thus, this peptide has been shown to reproduce at least one B-epitope, to which antibodies are raised during natural HCV infection. The synthesized 24-mer peptide is a promising candidate for further research and for use as a potential immunogen for the design of a nanoscale therapeutic immunogenic liposomal peptide composition with synthetic lipids as an adjuvant.
The aim of this study was to design promising variants of recombinant proteins based on NS4A antigen of hepatitis C virus (HCV) for subsequent work on the creation of a mosaic recombinant vaccine against hepatitis C. Methods. The recombinant proteins, containing different fragments of NS4A (belong to HCV subtype 1b) and murine interleukin-2, were prepared by genetic engineering approaches, using vectors pQE30 and pQE60 for E. coli. The size of the recombinant protein particles were evaluated by atomic force microscopy. Immunogenicity of these recombinant proteins was tested for Balb/c mice. The murine sera were analyzed by enzyme immunoassay. The recombinant proteins were also tested by immunoblotting with human sera specific to HCV antigens. Results. Six variants of recombinant genetic engineering constructions based on NS4A antigen of hepatitis C virus were designed. In the first variant amino acid sequence of NS4A was inserted using vector pQE60 into the immunodominant loop of HBc protein (core protein of hepatitis B virus). However, further analysis of the product showed the absence of virus-like particles in it. The following three constructs (with glycine linker 19s), without it and N-truncated NS4A) were done using vector pQE30. Only N-truncated NS4а product had a high expression level. Then new protein, consisted of NS4A and N-truncated murine interleukin-2 (IL-2), was obtained to enhance immunogenicity. It is known that IL-2 has adjuvant property. The new product (NS4a-IL-2) is well expressed, but it is accumulated in inclusion bodies. It was extracted with 7M guanidine chloride, purified on a Ni-sorbent and dialyzed in PBS. A shortened version of NS4A (ANS4a-IL-2) was also obtained with a high expression level. Taking in account that increasing the repetition of antigenic regions in recombinant constructs can enhance their immunogenicity, we obtained a recombinant protein comprising three repeat of NS4A. But its efficiency of expression was low. The construction NS4a had very poor immunogenicity, but NS4a-IL-2 (which contains the full length NS4A) displayed the best one for Balb/c mice. As it was shown earlier the immunogenicity of the protein preparation is dependent on the presence of aggregates, so we investigated our recombinant proteins for the presence of protein aggregates by atomic force microscopy.The presence of the particles with size of 6 - 8 nm was revealed in solution of NS4a-IL-2. Conclution. Only ANS4a-IL-2 and ANS4a-IL-2 of the six constructs had high expression and antigenic properties. And only NS4a-IL-2 possessed the high immunogenic property. So, this construction can be used for subsequent work on the creation of a mosaic recombinant vaccine against hepatitis C.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.